A leader in single cell and spatial biology, 10x Genomicsannounced the global launch of the next generation of its high-performance Flex assay, which features automation-compatible plate-based multiplexing.

This new platform marks a transformational step, delivering cost-effective and highly scalable single cell analysis that empowers researchers to massively scale both high cell-number applications, such as functional genomics CRISPR screens, and high-sample number applications like FFPE-based translational studies.

The assay utilizes a 96-well plate format that integrates seamlessly with 10x's automated cell partitioning, enabling researchers to profile up to 384 samples and an astounding 100 million cells per week. Built upon the proven Flex chemistry, the new assay maintains exceptional sensitivity and sequencing efficiency while supporting modular usage that reduces reagent waste and delivers more data at a lower cost, extending sophisticated single cell analysis to studies that previously had to rely on less granular bulk methods.

Michael Schnall-Levin, 10x Genomics' CTO, highlighted that this increased scalability and ease of use is critical for generating the high-quality biological data increasingly needed for AI-driven approaches. Early access customers enthusiastically endorsed the system, with Peter Skene from the Allen Institute calling the 384-plex Flex a "game changer" for profiling millions of cells at a fraction of the cost, thereby enabling exploration of functional immune responses with unprecedented depth. Similarly, Stephen Christensen of Pfizer noted that the new Flex delivers the company's "most streamlined and robust single cell profiling to date," predicting that the capability to multiplex entire studies will significantly accelerate drug discovery and development efforts.